(19) **Europäisches Patentamt / European Patent Office / Office européen des brevets**

(11) **EP 2 054 428 B9**

(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:
Corrected version no 1 (W1 B1)
Corrections, see
Claims EN 1

(48) Corrigendum issued on:
13.11.2013 Bulletin 2013/46

(45) Date of publication and mention
of the grant of the patent:
05.06.2013 Bulletin 2013/23

(21) Application number: **07840969.5**

(22) Date of filing: **15.08.2007**

(51) Int Cl.:
C07H 21/04 (2006.01)   *C12N 7/00* (2006.01)
A61K 39/00 (2006.01)   *A61K 39/12* (2006.01)
A61K 39/42 (2006.01)

(86) International application number:
PCT/US2007/076004

(87) International publication number:
WO 2008/022196 (21.02.2008 Gazette 2008/08)

(54) **DEVELOPMENT OF DENGUE VIRUS VACCINE COMPONENTS**

ENTWICKLUNG VON BESTANDTEILEN EINES IMPFSTOFFES GEGEN DAS DENGUE-VIRUS

DÉVELOPPEMENT DE COMPOSANTS D'UN VACCIN CONTRE LE VIRUS DE LA DENGUE

(84) Designated Contracting States:
**AT BE BG CH CY CZ DE DK EE ES FI FR GB GR
HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE
SI SK TR**

(30) Priority: **15.08.2006 US 837723 P**

(43) Date of publication of application:
06.05.2009 Bulletin 2009/19

(60) Divisional application:
12182319.9 / 2 589 602

(73) Proprietor: **The Government of the U.S.A., as repr.
by the
Secretary, Dept. of Health & Human Services, the
Nat. Inst. of Health
Rockville, MD 20852-3804 (US)**

(72) Inventors:
• **WHITEHEAD, Stephen, S.**
Montgomery Village, MD 20886 (US)
• **BLANEY, Joseph, E.**
Gettysburg, PA 17325 (US)
• **MURPHY, Brian, R.**
Bethesda, MD 20816 (US)
• **LAI, Ching-Juh**
Bethesda, Maryland 20817 (US)

(74) Representative: **Plougmann & Vingtoft A/S
Rued Langgaards Vej 8
2300 Copenhagen S (DK)**

(56) References cited:
WO-A-03/092592

• **BLANEY JOSEPH E ET AL: "Genetically
modified, live attenuated dengue virus type 3
vaccine candidates" AMERICAN JOURNAL OF
TROPICAL MEDICINE & HYGIENE, LAWRENCE,
KS, US, vol. 71, no. 6, 1 December 2004
(2004-12-01), pages 811-821, XP002399570 ISSN:
0002-9637**

• **WHITEHEAD S S ET AL: "Substitution of the
structural genes of dengue virus type 4 with those
of type 2 results in chimeric vaccine candidates
which are attenuated for mosquitoes, mice, and
rhesus monkeys" VACCINE, BUTTERWORTH
SCIENTIFIC. GUILDFORD, GB, vol. 21, no. 27-30,
1 October 2003 (2003-10-01), pages 4307-4316,
XP004462833 ISSN: 0264-410X**

• **DURBIN ANNA P ET AL: "rDEN2/4Delta30(ME), a
live attenuated chimeric dengue serotype 2
vaccine is safe and highly immunogenic in
healthy dengue-naïve adults." HUMAN
VACCINES 2006 NOV-DEC, vol. 2, no. 6,
November 2006 (2006-11), pages 255-260,
XP002507743 ISSN: 1554-8600**

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

(Cont. next page)

- **MEN R ET AL: "Dengue type 4 virus mutants containing deletions in the 3' noncoding region of the RNA genome: Analysis of growth restriction in cell culture and altered viremia pattern and immunogenicity in Rhesus monkeys"** JOURNAL OF VIROLOGY, THE AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 70, no. 6, 1 June 1996 (1996-06-01), pages 3930-3937, XP002109438 ISSN: 0022-538X

- **BLANEY J E ET AL: "DEVELOPMENT OF A LIVE ATTENUATED DENGUE VIRUS VACCINE USING REVERSE GENETICS" VIRAL IMMUNOLOGY, MARY ANN LIEBERT, INC., NEW YORK, US, vol. 19, no. 1, 1 April 2006 (2006-04-01), pages 10-32, XP008068928 ISSN: 0882-8245**

Description

Field of the Invention

[0001] The disclosure relates to mutations in the 3' untranslated region of the genome of dengue virus serotypes 1, 2, 3, and 4 that are useful in attenuating the growth characteristics of dengue virus vaccines.

Description of the Related Art

[0002] There are four serotypes of dengue virus (dengue virus type 1 [DEN1], DEN2, DEN3, and DEN4) that annually cause an estimated 50 to 100 million cases of dengue fever and 500,000 cases of the more severe form of dengue virus infection known as dengue hemorrhagic fever/dengue shock syndrome (Gubler, D. J. and M. Meltzer 1999 Adv Virus Res 53:35-70). Dengue virus is widely distributed throughout the tropical and semitropical regions of the world, and the number of dengue virus infections continues to increase due to the expanding range of its *Aedes aegypti* mosquito

vector. A vaccine is not available for the control of dengue disease despite its importance as a reemerging disease. The goal of immunization is to protect against dengue virus disease by the induction of a long-lived neutralizing antibody response against each of the four serotypes. Simultaneous protection against all four serotypes is required, since an increase in disease severity can occur in persons with preexisting antibodies to a heterotypic dengue virus. Such immunization can be achieved economically with a live, attenuated virus vaccine.

[0003] Dengue viruses are positive-sense RNA viruses belonging to the Flavivirus genus. The approximately 11,000-base genome contains a single open reading frame encoding a polyprotein which is processed by proteases of both viral and cellular origin into three structural proteins (C, prM, and E) and at least seven nonstructural (NS) proteins. Both ends of the dengue virus genome contain an untranslated region (UTR), and the overall genome organization is 5'-UTR-C-prM-E-NS1-NS2A-NS2B-NS3-NS4A-NS4B-NS5-UTR-3'. The 3' UTR is nearly 400 bases in length and is predicted

to contain several stem-loop structures conserved among dengue virus serotypes (Brinton, M. A. et al. 1986 Virology 153:113-121, Hahn, C. S. et al. 1987 J Mol Biol 198:33-41, Proutski, V. et al. 1997 Nucleic Acids Res 25:1194-1202, Rauscher, S. ct al. 1997 RNA 3:779-791, Shurtleff, A. et al. 2001 Virology 281:75-87). One such stem-loop structure, identified as TL-2 in the proposed secondary structure of the 3' UTR (Proutski, V. et al. 1997 Nucleic Acids Res 25: 1194-1202), was previously removed by deletion of 30 nucleotides from the DEN4 genome (3' nucleotides 172 to 143)

(Men, R. et al. 1996 J Virol 70:3930-3937) and has subsequently been designated as the Δ30 mutation (Durbin, A. P. et al. 2001 Am J Trop Med Hyg 65:405-413). The resulting virus, rDEN4Δ30, was shown to be attenuated in rhesus monkeys compared to parental viruses containing an intact TL-2 sequence and is attenuated in humans (Durbin, A. P. et al. 2001 Am J Trop Med Hyg 65:405-413).

Summary of the Invention

[0004] The disclosure is related to a dengue virus or chimeric dengue virus comprising a mutation in the 3' untranslated region (3'-UTR) selected from the group consisting of:

(a) a Δ30 mutation that removes the TL-2 homologous structure in each of the dengue virus serotypes 1, 2, 3, and 4, and nucleotides additional to the Δ30 mutation deleted from the 3'-UTR that removes sequence in the 5' direction as far as the 5' boundary of the TL-3 homologous structure in each of the dengue virus serotypes 1, 2, 3, and 4; and
(b) a replacement of the 3'-UTR of a dengue virus of a first serotype with the 3'-UTR of a dengue virus of a second serotype, optionally containing the Δ30 mutation and nucleotides additional to the Δ30 mutation deleted from the

3'-UTR;

and immunogenic compositions, methods of inducing an immune response, and methods of producing a dengue virus or chimeric dengue virus.

Brief Description of the Drawings

[0005]

Figure 1. Two approaches to attenuate dengue viruses. **A) (a-c)** Deletion of additional nucleotides from the 3'-UTR (DEN3 wt Sleman/78, **SEQ ID NO: 1). B)** Replacement of the 3'-UTR of a dengue virus of a first serotype with the 3'-UTR of a dengue virus of a second serotype.
Figures 2 - 5. Predicted secondary structure of the TL-1, TL-2 and TL-3 region of the 3'-UTR of each DEN serotype. The GenBank accession number of the sequence used for construction of each secondary structure model is

indicated. Only the last 278, 281, 276 and 281 nucleotides of DEN1, DEN2, DEN3, and DEN4, respectively, which comprise TL-1, TL-2 and TL-3, are used to avoid circularization of the structure and subsequent misfolding of known and experimentally-verified structural elements. The mfold program constraints specific for each structure model are indicated. Nucleotides that border the principle deletions are circled and numbered, with nucleotide numbering beginning at the 3' genome end (reverse-direction numbering system). Figure 2 - SEQ **ID NO: 2;** Figure 3 - **SEQ ID NO: 3;** Figure 4 - **SEQ ID NO: 4;** Figure 5 - **SEQ ID NO: 5.**

Figures 6 - 9. Δ30 deletion mutation depicted for each of the dengue virus serotypes DEN1, DEN2, DEN3 and DEN4. The Δ30 mutation deletes nt 174 to 145 of DEN1, nt 173 to 144 of DEN 2, nt 173 to 143 of DEN3, and nt 172 to 143 of DEN4, with reverse-direction numbering system. The deleted region is indicated by the Δ symbol. Figure 6 - **SEQ ID NO: 6;** Figure 7 - **SEQ ID NO: 7;** Figure 8 - **SEQ ID NO: 8;** Figure 9 - **SEQ ID NO: 9.**

Figures 10 - 13. Δ30/31 deletion mutation depicted for each of the dengue virus serotypes DEN1, DEN2, DEN3 and DEN4. In addition to the deletion of the nucleotides comprising the Δ30 mutation, the Δ31 mutation deletes nt 258 to 228 of DEN1, DEN2, DEN3, and DEN4, with reverse-direction numbering system. The deleted region is indicated by the Δ symbol. Figure 10 - **SEQ ID NO: 10;** Figure 11 - **SEQ ID NO: 11;** Figure 12 - **SEQ ID NO: 12;** Figure 13 - **SEQ ID NO: 13.**

Figures 14 - 17. Δ86 deletion mutation depicted for each of the dengue virus serotypes DEN1, DEN2, DEN3 and DEN4. The Δ86 mutation deletes nt 228 to 145 of DEN1, nt 228 to 144 of DEN 2, nt 228 to 143 of DEN3, and nt 228 to 143 of DEN4, with reverse-direction numbering system. The deleted region is indicated by the Δ symbol. Figure 14 - **SEQ ID NO: 14;** Figure 15 - **SEQ ID NO: 15;** Figure 16 - **SEQ ID NO: 16;** Figure **17 - SEQ ID NO: 17.**

Figure 18. Chimerization of rDEN3 with the rDEN4 or rDEN4Δ30 3'-UTR. **A)** Recombinant 3'-UTR chimeric dengue viruses were constructed by replacing the 3'-UTR of rDEN3 with regions derived from either rDEN4 or rDEN4Δ30. The relative location of the Δ30 mutation in the 3'-UTR is indicated by an arrow. The junctions between the ORF and UTR for rDEN3 and rDEN4 are indicated as junctions 1 and 2, respectively. Intertypic junction 3 is also indicated for the resulting chimeric viruses. **B)** Nucleotide and amino acid sequence of the junction regions are shown. For junction 3, nucleotide substitutions used to introduce a unique *HpaI* restriction enzyme recognition site are shown in lower case. Junction 1 - **SEQ ID NOs: 18** (nucleotide) and **19** (amino acid); Junction 2 - **SEQ ID NOs: 20** (nucleotide) and **21** (amino acid); Junction 3 - **SEQ ID NOs: 22** (nucleotide) and 23 (amino acid).

Figure 19. Replication in Vero cells and C6/36 cells. Four mutant viruses were compared to wild type rDEN3 for replication in Vero cells and C6/36 cells. 75 cm^2 flasks of confluent cells were infected at a multiplicity of infection of 0.01. Aliquots of 0.5 ml were removed from flasks daily for seven days. After addition of SPG to a concentration of 1X, samples were frozen on dry ice and stored at -80°C. Virus titer was determined by plaque assay on Vero cells for all samples. The limit of detection is 1.0 log$_{10}$PFU/ml.

Detailed Description of the Preferred Embodiment

Definitions

[0006] Unless defined otherwise, technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. See, *e.g.* Singleton P and Sainsbury D., Dictionary of Microbiology and Molecular Biology 3rd ed., J. Wiley & Sons, Chichester, New York, 2001, and Fields Virology 4th ed., Knipe D.M. and Howley P.M. eds, Lippincott Williams & Wilkins, Philadelphia 2001.

[0007] The term "about" means within 1, 2, or 3 nucleotides.

Mutant Dengue Viruses and Chimeric Dengue Viruses

[0008] A goal of the disclosure is to develop a set of type-specific, live attenuated dengue vaccine components that can be formulated into a safe, effective, and economical tetravalent dengue vaccine. The Δ30 mutation attenuates DEN4 in rhesus monkeys (Men, R. et al. 1996 J Virol 70:3930-3937)). The Δ30 mutation removes a homologous structure (TL-2) in each of the dengue virus serotypes 1, 2, 3, and 4 (Figure 2 - 5). However, the Δ30 mutation was found to not attenuate DEN3 in rhesus monkeys.

[0009] An embodiment of the invention provides dengue viruses and chimeric dengue viruses having one or more mutations that result in attenuation, methods of making such dengue viruses, and methods for using these dengue viruses to prevent or treat dengue virus infection. The mutation (or mutations) in the dengue virus of the invention is present in the 3' untranslated region (3'-UTR) formed by the most downstream approximately 384 nucleotides of the viral RNA, which have been shown to play a role in determining attenuation. The viruses and methods of the invention are described further, as follows.

[0010] One example of a dengue virus that can be used in the invention is the serotype 3, Sleman/78 strain. The applicability of the invention to all members of the dengue virus taxonomic group is inferred by the observation that the

properties of other dengue virus strains are similar to that of any one dengue virus strain. Dengue viruses have been grouped into four serotypes (DEN1, DEN2, DEN3 and DEN4). Numerous strains have been identified for each of the four serotypes. The complete genomic sequences of various dengue virus strains are provided as Genbank accession numbers in Table A.

Table A. Examples of Dengue Virus Strains

Serotype	Strain	Accession No.
1	02-20	AB178040
1	16007	AF180817
1	16007 PDK-13	AF180818
1	259par00	AF514883
1	280par00	AF514878
1	293arg00	AY206457
1	295arg00	AF514885
1	297arg00	AF514889
1	301arg00	AF514876
1	98901518	AB189120
1	98901530	AB189121
1	A88	AB074761
1	Abidjan	AF298807
1	ARG0028	AY277665
1	ARG0048	AY277666
1	ARG9920	AY277664
1	BR-90	AF226685
1	BR-01-MR	AF513110
1	BR-97-111	AF311956
1	BR-97-233	AF311958
1	BR-97-409	AF311957
1	Cambodia	AF309641
1	FGA-89	AF226687
1	FGA-NAd1d	AF226686
1	Fj231-04	DQ193572
1	GD05-99	AY376738
1	GD23-95	AY373427
1	GZ-80	AF350498
1	D1-hu-Yap-NIID27-2004	AB204803
1	D1-H-IMTSSA-98-606	AF298808
1	Mochizuki	AB074760
1	D1.Myanmar.059-01	AY708047
1	D1.Myanmar.194-01	AY713474
1	D1.Myanmar.206-01	AY713475

(continued)

Serotype	Strain	Accession No.
1	D1.Myanmar.23819-96	AY722802
1	D1.Myanmar.305-01	A713476
1	D1.Myanmar.31459-98	AY726555
1	D1.Myanmar.31987-98	AY726554
1	D1.Myanmar.32514-98	AY722803
1	D1.Myanmar.37726-01	A726549
1	D1.Myanmar.38862-01	AY726550
1	D1.Myanmar.40553-71	AY713473
1	D1.Myanmar.400568-76	AY722801
1	D1.Myanmar.444168-01	AY726551
1	D1.Myanmar.44988-02	AY726552
1	D1.Myanmar.49440-02	AY726553
1	rWestern Pacific-delta30	AY145123
1	Western Pacific rDEN1mutF	AY145122
1	S275-90	A75711
1	D1-hu-Seychelles-NIID41-2003	AB195673
1	Singapore 8114-93	AY762084
1	Singapore S275-90	M87512
1	ThD1 0008 81	AY732483
1	ThD1 0049 01	AY732482
1	ThD1 0081 82	AY732481
1	Thud1 0097 94	AY732480
1	ThD1 0102 01	AY732479
1	ThD1 0323 91	AY732478
1	ThD1 0336 91	AY732477
1	ThD1 0442 80	AY732476
1	ThD1 0488 94	AY732475
1	ThD1 0673 80	AY732474
1	Recombinant Western Pacific	AY145121
1	Nauru Island Western Pacific 45AZ5	NC 001477
1	Nauru Island, Western Pacific Bethesda	U88535
1	Nauru Island Western Pacific 45AZ5-PDK27	U88537
2	131	AF100469
2	16681-PDK53	M84728
2	16681 Blok	M84727
2	16681 Kinney	U87411
2	43	AF204178
2	44	AF204177

(continued)

Serotype	Strain	Accession No.
2	98900663	AB189122
2	98900665	AB189123
2	98900666	AB189124
2	BA05i	AY858035
2	Bangkok 1974	AJ487271
2	BR64022	AF489932
2	C0166	AF100463
2	C0167	AF100464
2	C0371	AF100461
2	C0390	AF100462
2	China 04	AF119661
2	Cuba115-97	AY702036
2	Cuba13-97	AY702034
2	Cuba165-97	A702038
2	Cuba205-97	A702039
2	Cuba58-97	AY702035
2	Cuba89-97	AY702037
2	DR23-01	AB122020
2	DR31-01	AB122021
2	DR59-01	AB122022
2	FJ-10	AF276619
2	FJ11-99	AF359579
2	I348600	AY702040
2	IQT1797	AF100467
2	IQT2913	AF100468
2	Jamaica-N.1409	M20558
2	K0008	AF100459
2	K0010	AF100460
2	Mara4	AF100466
2	DEN2-H-IMTSSA-MART-98-703	AF208496
2	New Guinea C	AF038403
2	New Guinea C-PUO-218 hybrid	AF038402
2	New Guinea-C	M29095
2	PDK-53	U87412
2	S1 vaccine	NC 001474
2	Tub16i	AY858036
2	ThD2 0017 98	DQ181799
2	ThD2 0026 88	DQ181802

(continued)

Serotype	Strain	Accession No.
2	ThD2 0038 74	DQ181806
2	ThD2 0055 99	DQ181798
2	ThD2 0078 01	DQ181797
2	ThD2 0168 79	DQ181805
2	ThD2 0263 95	DQ181800
2	ThD2 0284 90	DQ181801
2	ThD2 0433 85	DQ181803
2	ThD2 0498 84	DQ181804
2	ThNH-28-93	AF022435
2	ThNH29-93	AF169678
2	ThNH36-93	AF169679
2	ThNH45-93	A169680
2	ThNH-52-93	AF022436
2	ThNH54-93	AF169682
2	ThNH55-93	AF169681
2	ThNH62-93	AF169683
2	ThNH63-93	AF169684
2	ThNH69-93	AF169685
2	ThNH73-93	A169686
2	ThNH76-93	AF169687
2	ThNH81-93	AF169688
2	ThNH-p36-93	AF022441
2	ThNH-7-93	AF022434
2	ThNH-p11-93	AF022437
2	ThNH-p12-93	AF022438
2	ThNH-p14-93	AF022439
2	ThNH-p16-93	AF022440
2	Tonga-74	A744147
2	TSV01	AY037116
2	Taiwan-1008DHF	AY776328
2	Ven2	AF100465
3	D3-H-IMTSSA-MART-1999-1243	A099337
3	D3-H-IMTSSA-SRI-2000-1266	AY099336
3	80-2	AF317645
3	98901403	AB189125
3	98901437	AB189126
3	98901517	AB189127
3	98902890	AB189128

(continued)

Serotype	Strain	Accession No.
3	BA51	AY858037
3	BDH02-1	AY496871
3	BDH02-3	AY496873
3	BDH02-4	AY496874
3	BDH02-7	AY496877
3	BR74886-02	AY679147
3	C0331-94	AY876494
3	C0360-94	AY923865
3	den3 88	AY858038
3	den3 98	AY858039
3	FW01	AY858040
3	FW06	AY858041
3	H87	NC 001475
3	D3-Hu-TL018NIID-2005	AB214879
3	D3-Hu-TL029NIID-2005	AB214880
3	D3-Hu-TL109NIID-2005	AB214881
3	D3-Hu-TL129NIID-2005	AB214882
3	InJ 16 82	DQ401690
3	KJ30i	AY858042
3	KJ46	AY858043
3	KJ71	AY858044
3	mutant BDH02 01	DQ401689
3	mutant BDH02 03	DQ401691
3	mutant BDH02 04	DQ401692
3	mutant BDH02 07	DQ401693
3	mutant InJ_I6_82	DQ401694
3	mutant PhMH_J1_97	DQ401695
3	PF89-27643	AY744677
3	PF89-320219	AY744678
3	PF90-3050	AY744679
3	PF90-3056	AY744680
3	PF90-6056	AY744681
3	PF92-2956	AY744682
3	PF92-2986	A744683
3	PH86	AY858045
3	PhMH-J1-97	AY496879
3	PI64	AY858046
3	Singapore	A662691

(continued)

Serotype	Strain	Accession No.
3	Singapore 8120-95	AY766104
3	Sleman-78	AY648961
3	TB16	AY858047
3	TB55i	AY858048
3	ThD3_0007 87	AY676353
3	ThD3_0010 87	AY676353
3	ThD3_0055 93	AY676351
3	ThD3_0104 93	AY676350
3	ThD3 _1283_ 98	AY676349
3	ThD3_1687_98	AY676348
3	PFU92-4190	AY744684
3	PF94-136116	AY744685
3	Taiwan-739079A	AY776329
4	2A	AF375822
4	Recombinant clone rDEN4	AF326825
4	2Adel30	AF326826
4	814669	AF326573
4	B5	AF289029
4	rDEN4del30	AF326827
4	H241	AY947539
4	rDEN4	NC 002640
4	Singapore 8976-95	AY762085
4	SW38i	AY858050
4	ThD4 0017 97	AY618989
4	ThD4 0087 77	AY618991
4	ThD4 0348 91	AY618990
4	ThD4 0476 97	AY618988
4	ThD4 0485 01	AY618992
4	ThD4 0734 00	AY618993
4	Taiwan-2K0713	A776330
4	Unknown	M14931

[0011]   Mutations can be made in the 3'-UTR of a wild type infectious clone, *e.g..* dengue virus serotype 3, strain Sleman/78 or an infectious clone of another wild type, virulent dengue virus, and the mutants can then be tested in an animal model system (*e.g.*, in mouse and/or monkey model systems) to identify sites that cause attenuation. Attenuation is judged by, for example, detection of decreased viremia. One or more additional mutations found to attenuate the wild-type virus are optionally introduced into a wild type dengue virus, and these mutants are tested in an animal model system (*e.g.*, in a mouse and/or a monkey model system) to determine whether the resulting mutants are attenuated. Mutants that are found to be attenuated can then be used as new vaccine strains that have increased safety, due to attenuation.

[0012]   In addition to the viruses listed above, dengue viruses including chimeric dengue viruses that include one or

more attenuating mutations are included in the disclosure. These chimeras can consist of a dengue virus of a first serotype (i.e., a background dengue virus) in which a structural protein (or proteins) has been replaced with a corresponding structural protein (or proteins) of a dengue virus of a second serotype. For example, the chimeras can consist of a background dengue virus in which the prM and E proteins of the dengue virus of the first serotype have been replaced with the prM and E proteins of the dengue virus of the second serotype. The chimeric viruses can be made from any combination of dengue viruses of different serotypes. The dengue virus against which immunity is sought is the source of the inserted structural protein(s).

[0013]   As is noted above, mutations that are included in the viruses of the present invention arc attenuating. These mutations are present in the dengue virus 3'-UTR structure to attenuate the virus. Mutations can be made in the 3'-UTR using standard methods, such as site-directed mutagenesis. One example of the type of mutation present in the viruses of the disclosure is substitutions, but other types of mutations, such as deletions and insertions, can be used as well. In addition, as is noted above, the mutations can be present singly or in the context of one or more additional mutations.

[0014]   Referring to Figure 1, two approaches were taken to attenuate dengue virus. In one aspect, nucleotides additional to the Δ30 mutation were deleted from the 3'-UTR. In another aspect, the 3'-UTR of a dengue virus of a first serotype was replaced with the 3'-UTR from a dengue virus of a second serotype (optionally containing the Δ30 mutation and nucleotides additional to the Δ30 mutation deleted from the 3'-UTR).

Deletion of Nucleotides Additional to the Δ30 Mutation from the 3'-UTR

[0015]   Referring to Figures 2 - 5, using the first approach, the 3'-UTR of dengue viruses contain various conserved sequence motifs. The sequence of the DEN4 3'-UTR is illustrated in Figure 5. The genome of DEN4 strain 814669 contains 10,646 nucleotides, of which the last 384 nt at the 3' terminus are untranslated (non-coding). The locations of various sequence components in this region are designated with the reverse-direction numbering system. These sequences include the 3' distal secondary structure (nt 1 to 93), predicted to form stem-loop 1 (SL-1), which contains terminal loop 1 (TL=1). Nucleotides 117 183 form stem-loop 2 (SL-2) which contains TL-2. Nucleotides 201 - 277 form a pair of stem-loops (SL-3) which in part contains TL-3. Although the primary sequence of stem-loop 1 differs slightly among the dengue serotypes, the secondary structure is strictly conserved (compare Figures 2 - 5). Although the nucleotide spacing between SL-2 and neighboring SL-1 and SL-3 differ among the dengue virus serotypes, the overall structure of SL-2 is well-conserved. In addition, the exposed 9 nucleotides that comprise TL-2 are identical within all 4 dengue serotypes. It is TL-2 and its supporting stem structure that are removed by the Δ30 mutation (about nt 143 - 172). Removal of these 30 nucleotides results in formation of a new predicted structural element (SL-2Δ30) which has a primary sequence and secondary structure which is identical for each of the dengue virus serotypes (compare Figures 6 - 9).

[0016]   Figures 10 - 13 illustrate the approach where nucleotides additional to the Δ30 mutation are deleted from the 3'-UTR. The Δ30 mutation removes the TL-2 homologous structure in each of the dengue virus serotypes 1, 2. 3, and 4. The approach where nucleotides additional to the Δ30 mutation are deleted from the 3'-UTR) removes the TL-2 homologous structure and sequence up to and optionally including the TL-3 homologous structure so that the deletion extends as far as the 5' boundary of the TL-3 homologous structure in each of the dengue virus serotypes 1, 2, 3, and 4. In the approach illustrated in Figures 10 - 14, an additional deletion of about 31 nucleotides from TL-3 results in formation of a new predicted structural element (SL-3Δ31).

[0017]   Referring to Figures 14 - 17, the Δ86 mutation removes the TL-2 homologous structure and removes sequence up to the TL-3 homologous structure in each of the dengue virus serotypes DEN1, DEN2, DEN3 and DEN4. This deletion results in the formation of a new predicted structural element (SL-2Δ86).

[0018]   In some embodiments that involve deletion of nucleotides additional to the Δ30 mutation, nucleic acid deletions are made to the 3'-UTR structure of the dengue virus genome to attenuate the virus while maintaining its immunogenicity. The deletions include the Δ30 deletion (nt 173-143 of the serotype 3 Sleman/78 strain in an exemplary manner or corresponding thereto in other strains of DEN1, DEN2, DEN3, or DEN4; numbering is from the 3' end of the viral genome) in addition to deletion of additional 3'-UTR sequence that is contiguous or non-contiguous to the Δ30 deletion. The Δ30 deletion corresponds to the TL-2 structure of the 3'-UTR. One type of embodiment, termed rDEN1Δ30/31, rDEN2Δ30/31, rDEN3Δ30/31, or rDEN4Δ30/31 includes the original Δ30 deletion and a non-contiguous 31 nt deletion that removes both the original TL-2 and TL-3 structures. Another type of embodiment, termed rDEN1Δ61, rDEN2Δ61, rDEN3Δ61, or rDEN4Δ61 includes the Δ30 deletion and deletion of 31 contiguous nucleotides extending 3' from the Δ30 deletion. Another type of embodiment, termed rDEN1Δ86, rDEN2Δ86, rDEN3Δ86, or rDEN4Δ86, includes the Δ30 deletion and deletion of 56 contiguous nucleotides extending 5' from the Δ30 deletion. For DEN3, a complete list of mutant viruses constructed to contain 3'-UTR deletion mutations is presented below in Table 2.

Replacement of the 3'-UTR of a Dengue Virus of a First Scrotype with the 3'-UTR from a Dengue Virus of a Second Serotype

[0019] Using the second approach, the 3'-UTR of rDEN3 maybe replaced with the 3'-UTR of rDEN4, optionally containing the Δ30 mutation and nucleotides additional to the Δ30 mutation deleted from the 3'- UTR. Other examples include replacement of the 3'-UTR of rDEN3 with the 3'-UTR of dengue virus serotypes 1 and 2, optionally containing the Δ30 mutation and nucleotides additional to the Δ30 mutation deleted from the 3'-UTR. Other examples include: replacement of the 3'-UTR of rDEN with the 3'-UTR of dengue virus serotypes 2, 3, and 4, optionally containing the Δ30 mutation and nucleotides additional to the Δ30 mutation deleted from the 3'-UTR; replacement of the 3'-UTR of rDEN2 with the 3'-UTR) of dengue virus serotypes 1, 3, and 4, optionally containing the Δ30 mutation and nucleotides additional to the Δ30 mutation deleted from the 3'-UTR; and, replacement of the 3'-UTR of rDEN4 with the 3'-UTR of dengue virus serotypes 1, 2, and 3, optionally containing the Δ30 mutation and nucleotides additional to the Δ30 mutation deleted from the 3'-UTR.

[0020] Embodiments that involve replacement of the 3'-UTR of a dengue virus of a first serotype with the 3'-UTR of dengue virus of a second serotype include:

a) rDEN1-3'D2, rDEN1-3'D2x, rDEN1-3'D3, rDEN1-3'D3x, rDEN1-3'D4, rDEN1-3'D4x; rDEN1/2-3'D1, rDEN1/2-3'D1x, rDEN1/2-3'D3, rDEN1/2-3'D3x, rDEN1/2-3'D4, rDEN1/2-3'D4x; rDEN1/3-3'D1, rDEN1/3-3'D1x, rDEN1/3-3'D2, rDEN1/3-3'D2x, rDEN1/3-3'D4, rDEN1/3-3'D4x; rDEN14-3'D1, rDEN1/4-3'D1x, rDEN1/4-3'D2, rDEN1/4-3'D2x, rDEN1/4-3'D3, rDEN1/4-3'D3x;

b) rDEN2-3'D1, rDEN2-3'D1x, rDEN2-3'D3, rDEN2-3'D3x, rDEN2-3'D4, rDEN2-3'D4x; rDEN2/1-3'D2, rDEN2/1-3'D2x, rDEN2/1-3'D3, rDEN2/1-3'D3x, rDEN2/1-3'D4, rDEN2/1-3'D4x; rDEN2/3-3'D1, rDEN2/3-3'D1x, rDEN2/3-3'D2, rDEN2/3-3'D2x, rDEN2/3-3'D4, rDEN2/3-3'D4x; rDEN2/4-3'D1, rDEN2/4-3'D1x, rDEN2/4-3'D2, rDEN2/4-3'D2x, rDEN2/4-3'D3, rDEN2/4-3'D3x;

c) rDEN3-3'D1, rDEN3-3'D1x, rDEN3-3'D2, rDEN3-3'D2x, rDEN3-3'D4, rDEN3-3'D4x; rDEN3/1-3'D2, rDEN3/1-3'D2x, rDEN3/1-3'D3, rDEN3/1-3'D3x, rDEN3/1-3'D4, rDEN3/1-3'D4x; rDEN3/2-3'D1, rDEN3/2-3'D1x, rDEN3/2-3'D3, rDEN3/2-3'D3x, rDEN3/2-3'D4, rDEN3/2-3'D4x; rDEN3/4-3'D1, rDEN3/4-3'D1x, rDEN3/4-3'D2, rDEN3/4-3'D2x, rDEN3/4-3'D3, rDEN3/4-3'D3x; and

d) rDEN4-3'D1, rDEN4-3'D1x, rDEN4-3'D2, rDEN4-3'D2x, rDEN4-3'D3, rDEN4-3'D3x; rDEN4/1-3'D2, rDEN4/1-3'D2x, rDEN4/1-3'D3, rDEN4/1-3'D3x, rDEN4/1-3'D4, rDEN4/1-3'D4x; rDEN4/2-3'D1, rDEN4/2-3'D1x, rDEN4/2-3'D3, rDEN4/2-3'D3x, rDEN4/2-3'D4, rDEN4/2-3'D4x; rDEN4/3-3'D1, rDEN4/3-3'D1x, rDEN4/3-3'D2, rDEN4/3-3'D2x, rDEN4/3-3'D4, rDEN4/3-3'D4x;

where x is a mutation listed in Table 2.

Method of Making and Using Dengue or Chimeric Dengue Viruses

[0021] The viruses (including chimeric viruses) of the present invention can be made using standard methods in the art. For example, an RNA molecule corresponding to the genome of a virus can be introduced into host cells, *e.g.,* Vero cells, from which (or the supernatants of which) progeny virus can then be purified. In this method, a nucleic acid molecule (*e.g.*, an RNA molecule) corresponding to the genome of a virus is introduced into the host cells, virus is harvested from the medium in which the cells have been cultured, and the virus is formulated for the purposes of vaccination.

[0022] The viruses of the invention can be administered as primary prophylactic agents in adults or children at risk of infection, or can be used as secondary agents for treating infected patients. For example, in the case of DEN virus and chimeric DEN viruses, the vaccines can be used in adults or children at risk of DEN virus infection, or can be used as secondary agents for treating DEN virus-infected patients. Examples of patients who can be treated using the DEN virus-related vaccines and methods of the disclosure include (i) children in areas in which DEN virus is endemic, (ii) foreign travelers, (iii) military personnel, and (iv) patients in areas of a DEN virus epidemic. Moreover, inhabitants of regions into which the disease has been observed to be expanding (*e.g.*, beyond Sri Lanka, East Africa and Latin America), or regions in which it may be observed to expand in the future can be treated according to the disclosure.

[0023] Formulation of the viruses of the invention can be carried out using methods that are standard in the art. Numerous pharmaceutically acceptable solutions for use in vaccine preparation are well known and can readily be adapted for use in the present invention by those of skill in this art (see,.*e.g.*, Remington's Pharmaceutical Sciences (18th edition), ed. A. Gennaro, 1990, Mack Publishing Co., Easton, PA). The viruses can be diluted in a physiologically acceptable solution, such as sterile saline, sterile buffered saline, or L-15 medium. In another example, the viruses can be administered and formulated, for example, as a fluid harvested from cell cultures infected with dengue virus or chimeric dengue virus.

[0024] The vaccines of the disclosure can be administered using methods that are well known in the art, and appropriate

amounts of the vaccines administered can readily be determined by those of skill in the art. For example, the viruses of the invention can be formulated as sterile aqueous solutions containing between 10^2 and 10^7 infectious units (*e.g.*, plaque-forming units or tissue culture infectious doses) in a dose volume of 0.1 to 1.0 ml, to be administered by, for example, intramuscular, subcutaneous, or intradermal routes. Further, the vaccines of the disclosure can be administered in a single dose or, optionally, administration can involve the use of a priming dose followed by a booster dose that is administered, *e.g.,* 2-6 months later, as determined to be appropriate by those of skill in the art.

[0025] Optionally, adjuvants that are known to those skilled in the art can be used in the administration of the viruses of the invention. Adjuvants that can be used to enhance the immunogenicity of the viruses include, for example, liposomal formulations, synthetic adjuvants, such as (*e.g.*, QS21), muramyl dipeptide, monophosphoryl lipid A, or polyphosphazine. Although these adjuvants are typically used to enhance immune responses to inactivated vaccines, they can also be used with live vaccines.

Nucleic Acid Sequences

[0026] Nucleic acid sequences of DEN viruses are useful for designing nucleic acid probes and primers for the detection of deletion or chimeric 3'-UTRs in a sample or specimen with high sensitivity and specificity. Probes or primers corresponding to deletion or chimeric 3'-UTRs can be used to detect the presence of deletion or chimeric 3'-UTRs in general in the sample, to quantify the amount of deletion or chimeric 3'-UTRs in the sample, or to monitor the progress of therapies used to treat DEN virus infection. The nucleic acid and corresponding amino acid sequences are useful as laboratory tools to study the organisms and diseases and to develop therapies and treatments for the diseases.

[0027] Nucleic acid probes and primers selectively hybridize with nucleic acid molecules encoding deletion or chimeric 3'-UTRs or complementary sequences thereof. By "selective" or "selectively" is meant a sequence which does not hybridize with other nucleic acids to prevent adequate detection of the deletion or chimeric 3-UTRs. Therefore, in the design of hybridizing nucleic acids, selectivity will depend upon the other components present in the sample. The hybridizing nucleic acid should have at least 70% complementarity with the segment of the nucleic acid to which it hybridizes. As used herein to describe nucleic acids, the term "selectively hybridizes" excludes the occasional randomly hybridizing nucleic acids, and thus has the same meaning as "specifically hybridizing." The selectively hybridizing nucleic acid probes and primers of this disclosure can have at least 70%, 80%, 85%, 90%, 95%, 97%, 98% and 99% complementarity with the segment of the sequence to which it hybridizes, preferably 85% or more.

[0028] The present disclosure also contemplates sequences, probes and primers that selectively hybridize to the encoding nucleic acid or the complementary, or opposite, strand of the nucleic acid. Specific hybridization with nucleic acid can occur with minor modifications or substitutions in the nucleic acid, so long as functional species-species hybridization capability is maintained. By "probe" or "primer" is meant nucleic acid sequences that can be used as probes or primers for selective hybridization with complementary nucleic acid sequences for their detection or amplification, which probes or primers can vary in length from about 5 to 100 nucleotides, or preferably from about 10 to 50 nucleotides, or most preferably about 18-24 nucleotides. Isolated nucleic acids are provided herein that selectively hybridize with the species-specific nucleic acids under stringent conditions and should have at least five nucleotides complementary to the sequence of interest as described in Molecular Cloning: A Laboratory Manual, 2nd ed., Sambrook, Fritsch and Maniatis, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, 1989.

[0029] If used as primers, the composition preferably includes at least two nucleic acid molecules which hybridize to different regions of the target molecule so as to amplify a desired region. Depending on the length of the probe or primer, the target region can range between 70% complementary bases and full complementarity and still hybridize under stringent conditions. For example, for the purpose of detecting the presence of deletion or chimeric 3'-UTRs, the degree of complementarity between the hybridizing nucleic acid (probe or primer) and the sequence to which it hybridizes is at least enough to distinguish hybridization with a nucleic acid from other organisms.

[0030] The nucleic acid sequences of the disclosure include a diagnostic probe that serves to report the detection of a cDNA amplicon amplitied from the viral genomic RNA template by using a reverse-transcription/polymerase chain reaction (RT-PCR), as well as forward and reverse amplimers that are designed to amplify the cDNA amplicon. In certain instances, one of the amplimers is designed to contain a vaccine virus-specific mutation at the 3'-terminal end of the amplimer, which effectively makes the test even more specific for the vaccine strain because extension of the primer at the target site, and consequently amplification, will occur only if the viral RNA template contains that specific mutation.

[0031] Automated PCR-based nucleic acid sequence detection systems have been recently developed. TaqMan assay (Applied Biosystems) is widely used. A more recently developed strategy for diagnostic genetic testing makes use of molecular beacons (Tyagi and Kramer 1996 Nature Biotechnology 14:303-308). Molecular beacon assays employ quencher and reporter dyes that differ from those used in the TaqMan assay. These and other detection systems may be used by one skilled in the art.

Dengue virus type 3 (DEN3) vaccine components generated by introduction of deletions in the 3' untranslated region (UTR) or exchange of the DEN3 3'-UTR with that of DEN4

[0032] There are four dengue virus serotypes (DEN1, DEN2, DEN3, and DEN4) which circulate in tropical and sub-tropical regions of the world inhabited by more than 2.5 billion people (Gubler DJ 1998 Clin Microbiol Rev 11:480-496). DEN viruses are endemic in at least 100 countries and cause more human disease than any other arbovirus. Annually, there are an estimated 50-100 million dengue infections and hundreds of thousands of cases of dengue hemorrhagic fever/ shock syndrome (DHP/DSS), with children bearing much of the disease burden (Gubler DJ and Meltzer M 1999 Adv Virus Res 53:35-70). DHF/DSS remains a leading cause of hospitalization and death of children in at least eight southeast Asian countries (World Health Organization 1997 Dengue Haemorrhagic Fever: Diagnosis, Treatment, Prevention and Control, 2nd edition, WHO, Geneva). The dramatic increase in both the incidence and severity of disease caused by the four DEN serotypes over the past two decades is due in large part to the geographic expansion of the mosquito vectors, *Aedes aegypti* and *Aedes albopictus,* and the increased prevalence of the four DEN serotypes (Gubler DJ 1998 Clin Microbiol Rev 11:480-496). The dengue viruses are maintained in a life cycle of transmission from mosquito to human to mosquito with no other apparent viral reservoir participating in this life cycle in urban settings (Rice CM, 1996 in Flaviviridae: The viruses and their replication, Fields BN, Knipe DM, Howley PM, Chanock RM, Melnick JL, Monath TP, Roizman B, Straus SE, eds. Fields Virology. Philadelphia: Lippincott-Raven Publishers, pp. 931-959).

[0033] The DEN viruses, members of the Flaviviridae family, have spherical virions of approximately 40 to 60 nm which contain a single-stranded positive-sense RNA genome. A single polypeptide is co-translationally processed by viral and cellular proteases generating three structural proteins (capsid C, membrane M, and envelope E) and at least seven non-structural (NS) proteins. The genome organization of the DEN viruses is 5'-UTR-C-prM-E-NSI-NS2A-NS2B-NS3-NS4A-NS4B-NS5-UTR-3' (CTTR-untranslated region, prM-membrane precursor) (Rice CM, 1996 in Flaviviridae: The viruses and their replication, Fields BN, Knipe DM, Howley PM, Chanock RM, Melnick JL, Monath TP, Roizman B, Straus SE, eds. Fields Virology. Philadelphia: Lippincott-Raven Publishers, pp. 931-959).

[0034] In response to the increasing incidence and severity of DEN infection, development of vaccines is being pursued to prevent DEN virus disease. An economical vaccine that prevents disease caused by the DEN viruses has become a global public health priority. The cost-effectiveness, safety, and long-term efficacy associated with the live attenuated vaccine against yellow fever (YF) virus, another mosquito-borne flavivirus, serves as a model for the feasibility of developing of a live attenuated DEN virus vaccine (Monath TP, 1999 in Yellow fever, Plotkin SA, Orenstein WA, eds. Vaccines, Philadelphia: W.B. Saunders Co., 815-879). Additionally, an effective live attenuated Japanese encephalitis (JE) virus vaccine is used in Asia, and inactivated virus vaccines are available for JE and tick-borne encephalitis virus. The need for a vaccine against the DEN viruses is mounting, and, despite much effort, the goal of developing a safe and efficacious DEN virus vaccine has yet to be attained. An effective DEN virus vaccine must confer protection from each serotype because all four serotypes commonly circulate in endemic regions and secondary infection with a heterologous serotype is associated with increased disease severity.

[0035] We have employed two strategies for generating live attenuated vaccine components against each serotype that can then be combined into tetravalent formulations (Blaney JE et al. 2006 Viral Immunol. 19:10-32). First, reverse genetics has been used to introduce an attenuating 30 nucleotide deletion (Δ30) mutation into the 3'-UTR of cDNA clones of each DEN serotype (Durbin, AP et al. 2001 Am J Trop Med Hyg 65:405-413; Whitehead SS et al. 2003 J Virol 77:1653-1657; Blaney JE et al. 2004 Am J Trop Med Hyg 71:811-821: Blaney JE et al 2004 BMC Inf Dis 4:39). Initially, the rDEN4Δ30 vaccine component was found to be attenuated in rhesus monkeys (Table 1) and phase I/II clinical trials in humans have demonstrated that virus infection results in low viremia, is strongly immunogenic, and exhibits minimal reactogenicity with no observation of serious adverse events (Durbin, A. P. et al. 2001 Am J Trop Med Hyg 65:405-413; Durbin et al. 2005 J Inf Dis 191:710-718). Recently, the rDEN1Δ30 vaccine component, which was also attenuated in rhesus monkeys (Table 1), has been found to share a similar phenotype in clinical trials as that observed for rDEN430; low viremia, strong immunogenicity, and minimal reactogenicity in 20 volunteers (Whitehead SS et al. 2003 J Virol 77: 1653-1657; Blaney JE et al. 2006 Viral Immunol. 19:10-32). Unfortunately, the rDEN2Δ30 and rDEN2Δ30 vaccine components did not appear to be satisfaciorily attenuated in rhesus monkeys during pre-clinical testing and there is no plan to test these in humans (Table 1) (Blaney JE et al. 2004 Am J Trop Med Hyg 71:811-821; Blaney JE et al. 2004 BMC Inf Dis 4:39). Consequently, an alternative strategy for vaccine development has been generation of antigenic chimeric viruses by replacement of structural proteins of the attenuated rDEN4Δ30 vaccine component with those from DEN2 or DEN3 yielding the rDEN2/4Δ30 and rDEN3/4Δ30 vaccine components, respectively (Whitehead SS et al. 2003 Vaccine 21:4307-4316; Blaney JE et al. 2004 Am J Trop Med Hyg 71:811-821). The rDEN2/4Δ30 vaccine virus has been tested in humans and appears safe and strongly immunogenic, while clinical evaluation of the rDEN3/4Δ30 virus is currently planned.

Table 1. Effects of the Δ30 mutation on the four DEN serotypes in rhesus monkeys

Virus	Viremia[a]			Geometric mean neutralizing antibody titer[b]	Reference
	% of viremic monkeys	Mean no. of viremic days per monkey	Mean peak virus titer ($\log_{10}$PFU/ml ± SE)		
rDEN1	100	2.8	2.1 ± 0.1	1,230	Whitehead et al. J. Virol, 2003, 77:1653
rDEN1Δ30	50	0.5	0.8 ± 0.1	780	
rDEN2	100	4.0	1.9 ± 0.1	173	Blaney et al. BMC Inf Dis., 2004, 4:39
rDEN2Δ30	100	2.8	1.7 ± 0.2	91	
rDEN3	100	2.3	1.4 ± 0.2	363	Blaney et al. Am. J. Trop. Med. Hyg., 2004, 71:811
rDEN3Δ30	100	2.0	1.5 ± 0.2	265	
rDEN4	100	3.0	2.2 ± 0.2	322	Hanley et al. Vaccine, 2004, 22:3440
rDEN4Δ30	100	2.0	1.4 ± 0.2	154	

[a] Groups of rhesus monkeys were inoculated subcutaneously with 5.0 $\log_{10}$ PFU of the indicated virus in a 1ml dose. Serum was collected daily for 10 days. Virus titer in serum was determined by plaque assay in Vero cells.

[b] Plaque reduction (60%) neutralizing antibody titers were determined on day 28 serum using indicated wild type virus. Reciprocal dilution of geometric mean is indicated.

[0036]   Here, we describe novel vaccine components for the DEN3 serotype generated by genetic modification of the 3'-UTR of the DEN3 cDNA clone (Blaney JE et al. 2004 Am J Trop Med Hyg 71:811-821). Development of these DEN3 vaccine components, which possess the full complement of wild type DEN3 proteins, is important for two reasons. First, the present vaccine component for DEN3, rDEN3/4Δ30, may be found to be under- or over-attenuated in clinical trials. Second, an optimal vaccine for conferring protection from disease caused by DEN3 may require induction of T cell responses against the entire set of DEN3 proteins, rather than just the M and E which are the only DEN3 sequences present in the rDEN3/4Δ30 chimeric virus. To generate additional DEN3 vaccine components, novel deletions which encompass or border the Δ30 deletion in the 3'-UTR were introduced into the rDEN3 cDNA clone. Alternatively, the 3'-UTR of the rDEN3 cDNA clone was replaced with that of rDEN4 or rDEN4Δ30. Viable viruses were analyzed for attenuation phenotypes in tissue culture, SCID mice transplanted with HuH-7 cells, and rhesus monkeys. Three mutant viruses (rDEN3Δ30/31, rDEN3Δ86, and rDEN3-3'D4Δ30) have preclinical phenotypes which suggest they may be safe and immunogenic in humans.

Generation of rDEN3 deletion mutants

[0037]   We sought to generate expanded deletion mutations which include the original Δ30 (nt 173-143) mutation. Table 2 lists seven deletion mutations which encompass the original Δ30 mutation including Δ50, Δ61, Δ80, Δ86, Δ116A, Δ116B, and Δ146. In addition, the Δ30/31 mutation includes the original Δ30 mutation and a non-contiguous 31 nt deletion. The Δ31 mutation was also generated alone to discern the contribution of either Δ30 or Δ31 in the combined Δ30/31 deletion mutation. The location of bordering nucleotides of deletions in the predicted secondary structure of the DEN3 3'-UTR are indicated in Figure 4. In addition, the predicted secondary structure of the DEN3 3'-UTR for rDEN3Δ30, rDEN3Δ30/31, and rDEN3Δ86 are indicated in Figures 8, 12, and 16, respectively.

Table 2. Deletion mutations created in the 3'-UTR of DEN3 Sleman/78

Mutation	Deleted nucleotides[a]	Deletion junction
Δ30	173 - 143	-CCAAΔGACU-
Δ31	258 - 228	-CUGCΔGACU-
Δ50	192 - 143	-CACAAGACU-
Δ61	173 - 113	-CCGAΔUAAA-
Δ80	192 - 113	-CACAΔUAAA-
Δ86	228 - 143	-UAGCΔGACU-
Δ116 (A)	228 - 113	-UAGCΔUAAA-
Δ116 (B)	258 - 143	-CUGCΔGACU-
Δ146	258 - 113	-CUGCΔUAAA-
Δ30/31	173 - 143 258 - 228	-CCAAΔGACU- -CUGCΔGACU-
[a] Numbering is from the 3'-end of viral genome		

[0038] PCR mutagenesis was used to introduce the nine new deletion mutation into the DEN3 Sleman/78 cDNA plasmid, p3, which was previously used to generate the rDEN3Δ30 vaccine component (Blaney JE et al. 2004 Am J Trop Med Hyg 71:811-821). The p3-frag.4 cDNA subclone was used as the template for PCR reactions with indicated pairs of mutagenic oligonucleotides listed in Table 3, except for the Δ30/31 deletion mutation which used p3-frag.4Δ30 cDNA subclone as a template. PCR products were ligated and used to transform competent bacterial cells. Plasmid DNA was isolated from bacterial clones and the presence of the appropriate deletion mutation was confirmed by sequence analysis. To generate intact DEN3 cDNA plasmids containing the deletion mutations, the *Kpn*I-*Pst*I fragment (963 nt) from the mutated p3-frag.4 cDNA subclones were introduced into the p3-7164 cDNA plasmid. The p3-7164 plasmid encodes the 7164 Vero cell adaptation mutation which had previously been shown to enhance growth and transfection efficiency in Vero cells (Blaney JE et al. 2004 Am J Trop Med Hyg 71:811-821). Full length p3 plasmids containing the deletion mutations were confinned to contain the correct 3'-UTR sequence. Mutations in addition to the engineered deletions were identified in the rDEN3Δ30/31 and rDEN3Δ86 viruses when compared to the DEN3 p3 plasmid cDNA (Genbank # AY656169) (Table 4).

Table 3. Mutagenic primer sequences for construction of 3'-UTR deletions

Primer name	Sequence (5'→3')
113F	TAAAAACAGCATATTGACGCTGCGAG **(SEQ ID NO: 24)**
143F	GACTAGAGGTTAGAGGAGAC **(SEQ ID NO: 25)**
228F	GACTAGCGGTTAGAGGAGACCCC **(SEQ ID NO: 26)**
173R	TCGGGCCCCGCTGCTGCGTTG **(SEQ ID NO: 27)**
173R (for Δ30)	TTCGGCCCCGCTGCTGCGTTG **(SEQ ID NO: 28)**
192R	TGTGTCATGGGAGGGGTCTC **(SEQ ID NO: 29)**
228R	GCTACACCGTGCGTACAGCTTCC **(SEQ ID NO: 30)**
258R	GCAGCCTCCCAGGTTTTACGTCC **(SEQ ID NO: 31)**

Table 4. Mutations in addition to the engineered deletions that were identified in the rDEN3Δ30/31 and rDEN3Δ86 viruses when compared to the DEN3 p3 plasmid cDNA (Genbank # AY656169)

Virus	Gene	Nucleotide position	Nucleotide substitution	Amino acid position	Amino acid change
rDEN3Δ30/31	NS4B	7164[a]	U → C	115	Val → Ala
	NS4B	7398	C → U	193	Ala → Val
rDEN3Δ86	M	512	A → G	26	Lys → Glu
	NS3	6076	C → U	521	*silent*
	NS4B	7164[a]	U → C	115	Val → Ala
	NS5	8623	U → C	353	*silent*
	NS5	10267[b]	A → U	END	end → Tyr
	3'-UTR	10455	G → C	—	—

[a] The 7164 mutation is a Vero cell adaptation mutation which was engineered into the cDNA construct.

[b] There is a mixed population at this nt position (A→A/U) that changes the stop codon (UAA) at the end of NS5 to UAU which encodes Tyr. This would serve to extend NS5 by 2 amino acids (Tyr-Thr-End) because a stop codon remains at nts 10271-10273.

[0039] For recovery of viruses, 5'-capped RNA transcripts were synthesized in vitro from cDNA plasmids and transfected into either Vero cells or C6/36 cells. Prior to transcription and generation of infectious virus, the linker sequences were removed from cDNA plasmids by digestion with *Spe*I. Plasmids were then recircularized by ligation, linearized with *Acc*65I (isoschizomer of *Kpn*I which cleaves leaving only a single 3' nucleotide), and transcribed in vitro using SP6 polymerase. Purified transcripts were then transfected into Vero or C6/36 cells.

[0040] Recombinant viruses encoding each of the nine mutations, Δ30/31, Δ31, Δ50, Δ61, Δ80, Δ86, Δ116A, Δ116B, and Δ146, were successfully recovered in C6/36 cells, while only rDENΔ31 was recovered in Vero cells. The rDEN3 deletion mutant viruses were then passaged once in Vero cells followed by biological cloning by two terminal dilutions in Vero cells. Cloned viruses were then passaged two to seven times in Vero cells in an attempt to reach a stock titer of at least 6.0 $\log_{10}$PFU/ml which is considered sufficient to allow for cost-effective manufacture. Three recombinant viruses (rDEN3Δ50, rDEN3Δ116A, and rDEN3Δ146) were found to be excessively restricted for replication in Vero cells, despite being viable. Therefore, these three viruses were not studied further. The genetic sequence of the 3'-UTR was determined for the six remaining deletion mutant viruses that reached peak virus titers of at least 6.0 $\log_{10}$PFU/ml. The correct 3'-UTR sequence with the appropriate deletion was found for rDEN3Δ61, rDEN3Δ80, rDEN3Δ86 and rDEN3Δ30/31. However, two mutant viruses were found to contain additional deletions or mutations and were deemed to potentially have unstable genotypes. First, rDEN3Δ31 had the correct 3'-UTR deletion of nt 258-228 but also contained a 25 nt deletion of nt 222-198. Second, rDEN3Δ116B had the correct 3'-UTR deletion of nt 258-143 but also contained a 8 nt deletion of nt 430-423 and a single A->G substitution at nt 265. The potential of genetic instability with these viruses precludes their use as vaccine components so they were not further studied. Therefore, of the nine original deletions constructed, four mutant viruses were found to replicate efficiently in Vero cells and were studied further; rDEN3Δ61, rDEN3Δ80, rDEN3Δ86 and rDEN3Δ30/31.

Generation of rDEN3 chimeric viruses with the 3'-UTR derived from rDEN4 or rDEN4Δ30

[0041] Another strategy was employed to generate novel rDEN3 vaccine components; replacement of the 3'-UTR of the rDEN3 cDNA clone with that of rDEN4 or rDEN4Δ30 (Figure 18A). The 3'-UTR chimeric virus, rDEN3-3'D4Δ30, was designed to be a vaccine component for inclusion in tetravalent formulations which share the Δ30 deletion mutation

among all four serotypes. The rDEN3-3'D4 virus was designed to discern the contribution of the 3'-UTR chimerization and the Δ30 mutation to any observed phenotypes.

[0042] The p3-3'D4Δ30 plasmid was generated as follows. First, PCR mutagenesis was used to introduce a *Hpa*I restriction site into the p3-frag.4 cDNA subclone (Figure 18B). PCR products were ligated and used to transform competent bacterial cells. Plasmid DNA was isolated from bacterial clones and the presence of the appropriate deletion mutation was confirmed by sequence analysis. To introduce the rDEN4Δ30 3'-UTR into the p3-frag.4(*Hpa*I) cDNA subclone, a 364 nt fragment encompassing the p4Δ30 3'-UTR was amplified by PCR using a forward primer (5'-AACAACAACAAACACCAAAGGCTATTG-3', **SEQ ID NO: 32)** and reverse primer (5'-CCTACCGGTACCAGAACCT-GTTG-3', **SEQ ID NO: 33).** To generate the p3-frag.4-3'D4Δ30 cDNA subclone, the *Hpa*I-*Kpn*I fragment was removed from p3-frag.4(Hpal) and replaced with the p4Δ30 3'-UTR PCR fragment which had been cleaved by *Kpn*I. The *Pst*I-*Kpn*I fragment of p3-frag.4-3'D4Δ30 was introduced into the p3 plasmid to make the full length cDNA clone, p3-3'D4Δ30. The sequence of the 3'-UTR and NS5 junction were confirmed to be correct.

[0043] To generate p3-3'D4, the 30 deleted nucleotides of the Δ30 deletion mutation were introduced into the p3-frag. 4-3'D4Δ30 subclone. Briefly, the *Mlu*I-*Kpn*I fragment of p3-frag.4-3'D4Δ30, which encompasses the Δ30 region, was replaced with the corresponding fragment of p4 to make the plasmid, p3-frag.4-3'D4. To generate a full length p3 genome, the *Pst*I-*Kpn*I fragment of p3 was replaced with the corresponding fragment of p3-frag.4-3'D4. The 3'-UTR sequence of the p3-3'D4 plasmid was determined to be correct and contained the missing 30 nt of the Δ30 mutation.

[0044] For recovery of viruses, 5'-capped RNA transcripts were synthesized in vitro from cDNA plasmids and transfected into either Vero cells or C6/36 cells. Prior to transcription and generation of infectious virus, the linker sequences were removed from cDNA plasmids by digestion with *Spe*I. Plasmids were then recircularized by ligation, linearized with *Acc65*I (isoschizomer of *Kpn*I which cleaves leaving only a single 3' nucleotide), and transcribed *in vitro* using SP6 polymerase. Purified transcripts were then transfected into Vero or C6/36 cells.

[0045] rDEN3-3'D4 was recovered in C6/36 cells and Vero cells, while rDEN3-3'D4Δ30 could only be recovered in Vero cells. Mutant viruses were then passaged once in Vero cells followed by biological cloning by two terminal dilutions in Vero cells. rDEN3-3'D4 and rDEN3-3'D4Δ30 were then passaged four or six times in Vero cells, respectively. The genetic sequence of the NS5 - 3'-UTR junction and 3'-UTR was found to be correct for rDEN3-3'D4 and rDEN3-3'D4Δ30. Therefore, both viruses were studied further.

[0046] Mutations were also identified in the rDEN3-3'D4Δ30 virus compared to the DEN3 p3 plasmid cDNA clone (5'-UTR and genes) and DEN4 p4 cDNA clone (3'-UTR) (Table 5).

Table 5. Mutations in the rDEN3-3D4Δ30 virus compared to the DEN3 p3 plasmid cDNA clone (5'-UTR and genes) and DEN4 p4 cDNA clone (3'-UTR)

Virus	Gene	Nucleotide position	Nucleotide substitution	Amino acid position	Amino acid change
rDEN3-3'D4Δ30	C	250	U→C	52	*silent*
	NS3	5899	U→C	462	*silent*
	NS4Ba	7164	U→C	115	Val → Ala
	3'-UTR	10534	A→G	-	-

a The 7164 mutation is a Vero cell adaptation mutation which was engineered into the cDNA construct.

Replication of DEN3 mutant viruses in SCID-HuH-7 mice

[0047] The four deletion mutant viruses (rDEN3Δ30/31, rDEN3Δ61, rDEN3Δ80, and rDEN3Δ86) which were found to replicate to high titer in Vero cells and were confirmed to have the correct 3'-UTR sequence and the rDEN3-3'D4 and rDEN3-3'D4Δ30 viruses were first evaluated in SCID-HuH-7 mice. The rDEN3-3'D4 and rDEN3-3'D4Δ30 were compared to determine the effect on replication of the 3'-UTR chimerization and any further attenuation conferred by the Δ30 mutation. SCID-HuH-7 mice contain solid tumors of the HuH-7 human hepatoma cell line, and analysis of virus replication in this mouse model serves as a surrogate for DEN virus replication in the human liver. Numerous DEN virus mutant viruses have been identified by evaluation in SCID-HuH-7 mice (Blaney JE et al. 2002 Virology 300:125-139; Hanley et al. 2004 Vaccine 22:3440-3448; Blaney JE et al. 2006 Viral Immunol. 19:10-32). This mouse model provided the original evidence that the rDEN3Δ30 virus was not attenuated compared to parent virus rDEN3, while the antigenic chimeric virus, rDEN3/4Δ30, was approximately 100-fold restricted in replication in the SCID-HuH-7 mice when compared to wild type parent viruses (Blaney JE et al. 2004 Am J Trop Med Hyg 71:811-821).

[0048] For analysis of virus replication in SCID-HuH-7 mice, four to six week-old SCID mice (Tac:Icr:Ha(ICR)-*Prkdc*scid) (Taconic Farms) were injected intraperitoneally with 0.1 mL phosphate-buffered saline containing 10^7 HuH-7 cells which

had been propagated in tissue culture. Tumors were detected in the peritoneum five to six weeks after transplantation, and tumor-bearing mice were infected by direct inoculation into the tumor with 10^4 PFU of virus in 50 µl Opti-MEM I. Serum was collected from infected mice on day 7 post-infection and frozen at -80°C. The virus titer was determined by plaque assay in Vero cells.

[0049] As indicated in Table 6, wild type DEN3 Sleman/78 replicated to a mean peak virus titer of nearly $10^{6.9}$ PFU/ml. Although a decreased level of replication was observed for each of the six mutant viruses, the differences in replication were not statistically significant. However, rDEN3Δ86 and rDEN3-3'D4Δ30 were more than 10-fold restricted in replication compared to wild type DEN3 virus, while the replication of rDEN3Δ30/31 was slightly less than 10-fold restricted. On the basis of this arbitrary cut-off, these three viruses were selected for further evaluation. It is important to note that the rDEN4Δ30 virus which has a well-characterized, attenuation and non-reactogenic phenotype in humans was found to be only 6-fold restricted in replication in SCID-HuH-7 mice compared to wild type rDEN4 virus (Hanley et al. 2004 Vaccine 22:3440-3448).

Table 6. Replication of mutant DEN3 viruses in HuH-7-SCID mice.

Virus[1]	No. of mice	Mean peak virus titer ($\log_{10}$pfu/ml $\pm$ SE)	Fold-reduction compared to DEN3 (Sleman/78)
DEN3 (Sleman/78)	8	6.9 ± 0.1	-
rDEN3Δ30/31	8	6.0 ± 0.3	8
rDEN3Δ61	9	6.3 ± 0.2	4
rDEN3Δ80	9	6.3 ± 0.3	4
rDEN3Δ86	10	5.6 ± 0.4	20
rDEN3-3'D4	11	6.5 ± 0.4	3
rDEN3-3'D4Δ30	9	5.7 ± 0.2	16

[1]Groups of HuH-7-SCID mice were inoculated into the tumor with 4.0 $\log_{10}$ PFU of the indicated virus. Serum was collected on day 7 and virus titer was determined in Vero cells.

[0050] Because the rDEN3-3'D4Δ30 virus and the rDEN3Δ30/31 and rDEN3Δ86 viruses encode the full set of DEN3 structural and non-structural proteins, they would be expected to induce the full complement of humoral and cellular immunity. This more complete immune induction would be advantageous compared to that induced by the chimeric rDEN3/4Δ30, which encodes only the structural proteins of DEN3.

Replication of DEN3 mutant viruses in tissue culture

[0051] The level of virus replication in Vero cells and mosquito C6/36 cells was assessed for the rDEN3Δ30/31 and rDEN3Δ86 deletion mutant viruses and the rDEN3-3'D4 viruses with and without Δ30. Replication in Vero cells was analyzed because these cells are the substrate for manufacture, while growth in C6/36 cells was assessed because attenuation phenotypes in these mosquito cells may be associated with restricted replication in Aedes mosquitoes which serve as the vector for DEN virus transmission (Hanley et al. 2003 Virology 312:222-232).

[0052] Growth kinetics were evaluated as follows. Confluent monolayers of Vero cells and C6/36 cells in 75 cm^2 flasks were infected at a multiplicity of infection of 0.01. Aliquots of 0.5 ml tissue culture supernatant were removed daily for seven days, combined with SPG stabilizer, and frozen at -80°C. Virus titer of all samples was determined by plaque assay in Vero cells. The limit of detection for the plaque assay is 1.0 $\log_{10}$PFU/ml.

[0053] The replication kinetics of each virus in both cell lines is shown in Figure 19. In Vero cells, rDEN3Δ30/31, rDEN3Δ86, and rDEN3-3'D4Δ30 replicated to a peak level that approximated that of wild type rDEN3 and with similar kinetics to that of wild type rDEN3. These three vaccine components reached peak virus titers of 6.5 to 6.7 $\log_{10}$PFU/ml which demonstrates the feasibility of manufacture for each of these viruses. In Vero cells, the rDEN3-3'D4 virus replicated to a peak titer of 7.8 $\log_{10}$PFU/ml which is nearly 100-fold higher than that observed for wild type rDEN3 indicating that inclusion of the DEN4 3'-UTR may augment replication in Vero cells. This could also be attributed to more efficient Vero cell adaptation of the rDEN3-3'D4 virus. rDEN4 replicates to a peak titer of approximately 8.0 $\log_{10}$PFU/ml which indicates that the chimeric virus achieves a peak titer that does not exceed that of either of its parent viruses (Blaney JE et al. 2006 Viral Immunol. 19:10-32).

[0054] Analysis of virus replication in C6/36 cells demonstrated that rDEN3Δ86 and rDEN3-3'D4Δ30 reached peak titers approximately 10-fold lower than the peak virus titer of wild type rDEN3 virus, 6.9 $\log_{10}$PFU/ml (Figure 19). The rDEN3-3'D4 virus replicated to a peak titer similar to that observed for wild type rDEN3. The most striking result was the lack of replication observed in C6/36 cells for the rDEN3Δ30/31 virus. After day 1, virus was not detected in culture

medium from C6/36 cells infected with rDEN3Δ30/31 virus despite the efficient replication observed in Vero cells. These results were confirmed in a second independent growth curve experiment and indicate a host range attenuation phenotype in tissue culture which is envisioned as being accompanied by an attenuation phenotype in mosquitoes as well.

Replication and immunogenicity of DEN3 mutant viruses in rhesus monkeys

[0055]   Based on the slight attenuation in SCID-HuH-7 mice and efficient growth in Vero cells, rDEN3Δ30/31, rDEN3Δ86, and rDEN3-3'D4Δ30 were evaluated in rhesus monkeys. The mutant viruses were compared with wild type DEN3 for level and duration of viremia, neutralizing antibody induction, and the ability to confer protection from wild type DEN3 virus challenge. The rDEN3-3'D4 virus was also evaluated to discern the contribution of the 3'-UTR chimerization upon attenuation with and without the Δ30 mutation. An attenuation phenotype in rhesus monkeys has generally been a strong predictor of safety for vaccine components in clinical trials including rDEN4Δ30, rDEN1Δ30, and rDEN2/4Δ30 (Blaney JE et al. 2006 Viral Immunol. 19:10-32).

[0056]   Groups of four rhesus monkeys were inoculated subcutaneously with 10^5 PFU of the indicated viruses (Table 7). Two monkeys were mock infected with virus diluent. For detection of viremia, serum was collected on days 0-8 and on day 10 and frozen at -80°C. Virus titer in serum samples was determined by plaque assay in Vero cells. Serum was collected on day 28 for detection of neutralizing antibodies directed against DEN3. Levels of neutralizing antibodies were determined using a plaque reduction neutralization assay in Vero cells against wild type DEN3 virus. On day 35 post-infection, all monkeys were challenged by subcutaneous infection with 10^5 PFU DEN3 wild type virus. Serum was collected on days 0-8 and on day 10 and frozen at -80°C. Virus titer in serum samples was determined by plaque assay in Vero cells. *

Table 7. Replication and immunogenicity of rDEN3 mutant viruses in rhesus monkeys,

Virus[1]	No. of monkeys	%of monkeys with viremia	Mean no. of viremic daysper monkey	Mean peak virus titer[2] ($\log_{10}$pfu/ml ± SE)	Geometric mean serum neutralizing antibody titer (reciprocal dilution)[3]		Post-challenge[4]	
					Day 0	Day 28	% of monkeys with viremia	Mean peak virus titer[2] ($\log_{10}$pfu/ml ± SE)
DEN3 (Sleman/78)	4	100	3.5	1.8 ± 0.1	< 5	253	0	< 1.0
rDEN3Δ30/31	4	0	0	< 1.0	< 5	304	0	< 1.0
rDEN3Δ86	4	0	0	< 1.0	< 5	224	0	< 1.0
rDEN3-3'D4	4	75	1.5	1.3 ± 0.2	< 5	229	0	< 1.0
rDEN3-3'D4Δ30	4	0	0	< 1.0	< 5	77	0	< 1.0
mock infected	2	0	0	< 1.0	< 5	< 5	100	1.8 ± 0.2

[1] Groups of rhesus monkeys were inoculated subcutaneously on day 0 with 5.0 $\log_{10}$ PFU of the indicated virus in a 1ml dose. Serum was collected daily on days 0 - 8 and 10 and once on day 28.
[2] Virus titer in serum was determined by plaque assay in Vero cells.
[3] Plaque reduction (60%) neutralizing antibody titers were determined using DEN3 (Sleman78).
[4] Monkeys were challenged after 35 days with DEN3 (Sleman/78) administered subcutaneously in a 1 ml dose containing 5.0 $\log_{10}$ PFU. Serum was collected daily on days 0 - 8 and 10.

[0057]   Wild type DEN3 Sleman/78 virus replicated in rhesus monkeys to a mean peak virus titer of 1.8 $\log_{10}$PFU/ml serum with all monkeys developing viremia (Table 7). These results parallel previous studies of DEN3 in rhesus monkeys (Blaney JE et al. 2004 Am J Trop Med Hyg 71:811-821). No viremia was detected in any monkey infected with any of the three vaccine components, rDEN3Δ30/31, rDEN3Δ86, or rDEN3-3'D4Δ30 demonstrating a clear attenuation phenotype for each of these viruses in rhesus monkeys. Interestingly, the rDEN3-3'D4 virus was detected in 75% of monkeys with a mean peak virus titer of 1.3 $\log_{10}$PFU/ml serum suggesting that the presence of the Δ30 mutation is critical for attenuation of the 3'-UTR chimeric virus. Despite the lack of detectable viremia, mean neutralizing antibody levels in monkeys infected with rDEN3Δ30/31 and rDEN3Δ86 reached levels similar to that of wild type DEN3 virus, 1:253 (Table 7). In contrast, the rDEN3-3'D4Δ30 virus induced mean neutralizing antibody levels approximately three-fold lower than DEN3. However, 100% of monkeys immunized with each vaccine component seroconverted as defined by a four-fold

or greater rise in serum neutralizing antibody levels after infection. Thus all monkeys were deemed to be infected by each of the vaccine components despite the lack of detectable viremia. Determination of virus titer in serum after challenge with DEN3 virus indicated that immunization with each of the vaccine components induced complete protection from detectable viremia as would be expected given the observed neutralizing antibody levels.

Replication in mosquitoes.

[0058]   Replication of rDEN3 and rDEN3Δ30/31 was studied in *Toxorynchites amboinenesis* mosquitoes. Intrathoracic inoculation of serial ten-fold dilutions of test virus was performed as described previously (Troyer J.M. e al. 2001 Am. J. Trop. Med. Hyg. 65:414-9). After a 14 day incubation, heads were separated and homogenized in diluent. Virus titer in head homogenates was determined by plaque assay in Vero cells.

[0059]   Based on the attenuation of rDEN3Δ30/31 in rhesus monkeys and its restricted replication in C6/36 mosquito cells, rDEN330/31 was compared to wild type rDEN3 for infectivity and level of replication in highly sensitive *Toxorynchites amboinensis* mosquitoes (Table 8). Ten-fold serial dilutions of virus were inoculated intrathoracically, and the ability to infect head tissues was evaluated by performing a plaque assay on mosquito head homogenates after a 14 day incubation. The infectivity of rDEN3 and rDENΔ30/31 was very similar as the 50% mosquito infectious dose was approximately $10^{1.3}$ PFU for both viruses (Table 8). However, the level of replication of rDEN330/31 in the heads of infected mosquitoes was about 5- to 50-fold reduced. This reduction was significant at the $10^{2.3}$ and $10^{1.3}$ PFU doses tested. This finding indicates that although rDENΔ30/31 has infectivity for *Toxorynchites* by intrathoracic infection similar to that of wild type rDEN3, there is a statistically significant restriction in the level of replication in mosquitoes afforded by the Δ30/31 mutation.

Table 8. Replication of rDEN3 and rDEN3Δ30/31 in *Toxorynchites amboinensis*

Virus	Dose[a] ($\log_{10}$PFU)	No tested	% infected[b]	Mean virus titer[c] ($\log_{10}$PFU/head)	Reduction ($\log_{10}$) compared to same dose of wt virus
rDEN3 wt	2.3	20	90	4.2 ± 0.1[d]	
	1.3	19	53	4.2 + 0.1[e]	
	0.3	17	18	4.3 ± 0.3	
rDEN3Δ30/31	2.3	12	83	2.7 ± 0.3[d]	1.5
	1.3	16	44	3.1 ± 0.3[e]	1.1
	0.3	8	13	3.6 ± 0.0	0.7

[a] Virus titer administered intrathoracically in a 0.2 μl inoculum.
[b] Percentage of mosquitoes with detectable virus at day 14 post-inoculation was determined by plaque assay on mosquito head homogenates in Vero cells.
[c] Calculated using only values of virus-positive heads.
[d] For $10^{2.3}$ PFU dose of rDEN3 and rDEN3Δ30/31, mean virus titers were significantly different as determined by a Tukey-Kramer post-hoc test (P < 0.001).
[e] For $10^{1.3}$ PFU dose of rDEN3 and rDEN3Δ30/31, mean virus titers were significantly different as determined by a Tukey-Kramer post-hoc test (P < 0.005).

[0060]   While the present invention has been described in some detail for purposes of clarity and understanding, one skilled in the art will appreciate that various changes in form and detail can be made without departing from the true scope of the invention.

SEQUENCE LISTING

[0061]

<110> The Government of the United States of America, as represented by the
Secretary, Department of Health and Human services whitehead, Stephen S.
Blaney, Joseph E.
Murphy, Brian R.

<120> DEVELOPMENT OF DENGUE VIRUS VACCINE COMPONENTS

<130> NIH343.001VPC

<150> US 60/837,723
<151> 2006-08-15

<160> 33

<170> FastSEQ for windows version 4.0

<210> 1
<211> 276
<212> DNA
<213> Dengue virus

<400> 1

```
uaaaaccugg gaggcugcaa acuguggaag cuguacgcac ggguguagcag acuagcgguu  60
agaggagacc ccucccauga cacaacgcag cagcggggcc cgagcucuga gggaagcugu  120
accuccuugc aaaggacuag agguuagagg agaccccccg caaauaaaaa cagcauauug  180
acgcugggag agaccagaga uccugcuguc uccucagcau cauuccaggc acagaacgcc  240
agaaaaugga auggugcugu ugaaucaaca gguucu                           276
```

<210> 2
<211> 278
<212> DNA
<213> Dengue virus

<400> 2

```
uaaaaacccg ggaggcugca aaccauggaa gcuguacgca uggggguagca gacuaguggu  60
uagaggagac cccucccaag acacaacgca gcagcggggc ccaacaccag gggaagcugu  120
acccguggugg uaaggacuag agguuagagg agaccccccg cacaacaaca aacagcauau  180
ugacgcuggg agagaccaga gauccugcug ucucuacagc aucauuccag gcacagaacg  240
ccagaaaaug gaauggugcu guugaaucaa cagguucu                         278
```

<210> 3
<211> 281
<212> DNA
<213> Dengue virus

<400> 3

```
uaaaaaaucc gggaggccac aaaccauggga agcuguacgc auggcguagu ggacuagcgg  60
uuagaggaga ccccucccuu acagaucgca gcaacaaugg gggcccaagg ugagaugaag  120
cuguagucuc acuggaagga cuagagguua gaggagaccc ccccaaaaca aaaaacagca  180
uauugacgcu gggaaagacc agagauccug cugucuccuc agcaucauuc caggcacagg  240
acgccagaaa auggaauggu gcuguugaau caacagguuc u                     281
```

<210> 4
<211> 276
<212> DNA
<213> Dengue virus

<400> 4

```
uaaaaccugg gaggcugcaa acuguggaag cuguacgcac gguguagcag acuagcgguu  60
agaggagacc ccucccauga cacaacgcag cagcggggcc cgagcucuga gggaagcugu  120
accuccuugc aaaggacuag agguuagagg agaccccccg caaauaaaaa cagcauauug  180
acgcugggag agaccagaga uccugcuguc uccucagcau cauuccaggc acagaacgcc  240
agaaaaugga auggugcugu ugaaucaaca gguucu                            276
```

<210> 5
<211> 281
<212> DNA
<213> Dengue virus

<400> 5

```
auccccaggg aggccaugcg ccacggaagc uguacgcgug gcauauugga cuagcgguua  60
gaggagaccc cucccaucac ugacaaaacg cagcaaaagg gggcccgaag ccaggaggaa  120
gcuguaccuc ugguggaagg acuagagguu agaggagacc cccccaacac aaaaacagca  180
uauugacgcu gggaaagacc agagauccug cugucucugc aacaucaauc caggcacaga  240
gcgccgcaag auggauuggu guuguugauc caacagguuc u                      281
```

<210> 6
<211> 248
<212> DNA
<213> Artificial Sequence

<220>
<223> Dengue virus construct

<400> 6

```
uaaaaacccg ggaggcugca aaccauggaa gcuguacgca uggggguagca gacuaguggu  60
uagaggagac cccucccaag acacaacgca gcagcggggc ccaagacuag agguuagagg  120
agaccccccg cacaacaaca aacagcauau ugacgcuggg agagaccaga gauccugcug  180
ucucuacagc aucauuccag gcacagaacg ccagaaaaug gaauggugcu guugaaucaa  240
cagguucu                                                          248
```

<210> 7
<211> 251
<212> DNA
<213> Artificial Sequence

<220>
<223> Dengue virus construct

<400> 7

```
uaaaaaaucc gggaggccac aaaccaugga agcuguacgc auggcguagu ggacuagcgg  60
uuagaggaga cccucucccuu acagaucgca gcaacaaugg gggcccaaga cuagagguua  120
gaggagaccc ccccaaaaca aaaaacagca uauugacgcu gggaaagacc agagauccug  180
cugucuccuc agcaucauuc caggcacagg acgccagaaa auggaauggu gcuguugaau  240
caacagguuc u                                                      251
```

<210> 8
<211> 245
<212> DNA
<213> Artificial sequence

<220>
<223> Dengue virus construct

<400> 8

```
uaaaaccugg gaggcugcaa acuguggaag cuguacgcac ggguuagcag acuagcgguu 60
agaggagacc ccucccauga cacaacgcag cagcggggcc caagacuaga gguuagagga 120
gaccccccgc aaauaaaaac agcauauuga cgcugggaga gaccagagau ccugcugucu 180
ccucagcauc auuccaggca cagaacgcca gaaauggaa uggugcuguu gaaucaacag 240
guucu 245
```

<210> 9
<211> 250
<212> DNA
<213> Artificial sequence

<220>
<223> Dengue virus construct

<400> 9

```
auccccaggg aggccaugcg ccacggaagc uguacgcgug gcauauugga cuagcgguua 60
gaggagaccc cucccaucac ugacaaaacg cagcaaaagg gggcccaaga cuagagguua 120

gaggagaccc ccccaacaca aaaacagcau auugacgcug ggaaagacca gagauccugc 180
ugucucugca acaucaaucc aggcacagag cgccgcaaga uggauugguug uuguugaucc 240
aacagguucu 250
```

<210> 10
<211> 217
<212> DNA
<213> Artificial sequence

<220>
<223> Dengue virus construct

<400> 10

```
uaaaaacccg ggaggcugca acuagugguu agaggagacc ccucccaaga cacaacgcag 60
cagcggggcc caagacuaga gguuagagga gaccccccgc acaacaacaa acagcauauu 120
gacgcuggga gagaccagag auccugcugu cucuacagca ucauuccagg cacagaacgc 180
cagaaaaugg aauggugcug uugaaucaac agguucu 217
```

<210> 11
<211> 220
<212> DNA
<213> Artificial sequence

<220>
<223> Dengue virus construct

<400> 11

```
uaaaaaaucc gggaggccac aaauagcggu uagaggagac cccucccuua cagaucgcag 60
caacaauggg ggcccaagac uagagguuag aggagacccc cccaaaacaa aaaacagcau 120
auugacgcug ggaaagacca gagauccugc ugucuccuca gcaucauucc aggcacagga 180
cgccagaaaa uggaauggug cuguugaauc aacagguucu 220
```

<210> 12
<211> 214

<212> DNA
<213> Artificial sequence

<220>
<223> Dengue virus construct

<400> 12

```
uaaaaccugg gaggcugcga cuagcgguua gaggagaccc cucccaugac acaacgcagc  60
agcggggccc aagacuagag guuagaggag accccccgca aauaaaaaca gcauauugac 120
gcugggagag accagagauc cugcugucuc cucagcauca uuccaggcac agaacgccag 180
aaaauggaau ggugcuguug aaucaacagg uucu                             214
```

<210> 13
<211> 219
<212> DNA
<213> Artificial sequence

<220>
<223> Dengue virus construct

<400> 13

```
auccccaggg aggccaugcg ccacgguuag aggagacccc ucccaucacu gacaaaacgc  60
agcaaaaggg ggcccaagac uagagguuag aggagacccc cccaacacaa aaacagcaua 120
uugacgcugg gaaagaccag agauccugcu gucucugcaa caucaaucca ggcacagagc 180
gccgcaagau ggauuggugu uguugaucca acagguucu                        219
```

<210> 14
<211> 194
<212> DNA
<213> Artificial sequence

<220>
<223> Dengue virus construct

<400> 14

```
uaaaaacccg ggaggcugca aaccauggaa gcuguacgca ugggguagca gacuagaggu  60
uagaggagac ccccgcaca acaacaaaca gcauauugac gcugggagag accagagauc 120
cugcugucuc uacagcauca uuccaggcac agaacgccag aaaauggaau ggugcuguug 180
aaucaacagg uucu                                                   194
```

<210> 15
<211> 196
<212> DNA
<213> Artificial sequence

<220>
<223> Dengue virus construct

<400> 15

```
uaaaaaaucc gggaggccac aaaccaugga agcuguacgc auggcguagu ggagacuaga  60
gguuagagga gacccccca aaacaaaaaa cagcauauug acgcugggaa agaccagaga 120
uccugcuguc uccucagcau cauuccaggc acaggacgcc agaaaaugga auggugcugu 180
ugaaucaaca gguucu                                                 196
```

<210> 16
<211> 190
<212> DNA
<213> Artificial Sequence

<220>
<223> Dengue virus construct

<400> 16

```
uaaaaccugg gaggcugcaa acuguggaag cuguacgcac gguguagcga cuagagguua 60
gaggagaccc cccgcaaaua aaaacagcau auugacgcug ggagagacca gagauccugc 120
ugucuccuca gcaucauucc aggcacagaa cgccagaaaa uggaauggug cguuugaauc 180
aacagguucu                                                       190
```

<210> 17
<211> 195
<212> DNA
<213> Artificial Sequence

<220>
<223> Dengue virus construct

<400> 17

```
auccccaggg aggccaugcg ccacggaagc uguacgcgug gcauauugga cuagacuaga 60
gguuagagga gaccccccca acacaaaaac agcauauuga cgcugggaaa gaccagagau 120
ccugcugucu cugcaacauc aauccaggca cagagcgccg caagauggau ugguuuguu 180
gauccaacag guucu                                                 195
```

<210> 18
<211> 39
<212> DNA
<213> Artificial Sequence

<220>
<223> Junction region

<400> 18
gagggagcca tttggtaaac gtaggaagtg aaaaagagg   39

<210> 19
<211> 5
<212> PRT
<213> Artificial sequence

<220>
<223> Junction region

<400> 19

```
Glu Gly Ala Ile Trp
1               5
```

<210> 20
<211> 39
<212> DNA

<213> Artificial sequence

<220>
<223> Junction region

<400> 20
agtgaaggag ttctgtaatt accaacaaca aacaccaaa   39

<210> 21
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> Junction region

<400> 21

```
                          Ser Glu Gly Val Leu
                          1               5
```

<210> 22
<211> 39
<212> DNA
<213> Artificial Sequence

<220>
<223> Junction region

<400> 22
gagggagcca tttggtagtt aacaacaaca aacaccaaa   39

<210> 23
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> Junction region

<400> 23

```
                          Glu Gly Ala Ile Trp
                          1               5
```

<210> 24
<211> 26
<212> DNA
<213> Artificial Sequence

<220>
<223> synthetic primer

<400> 24
taaaaacagc atattgacgc tgggag   26

<210> 25
<211> 20

<212> DNA
<213> Artificial Sequence

<220>
<223> synthetic primer

<400> 25
gactagaggt tagaggagac   20

<210> 26
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<223> synthetic primer

<400> 26
gactagcggt tagaggagac ccc   23

<210> 27
<211> 21
<212> DNA
<213> Artificial sequence

<220>
<223> synthetic primer

<400> 27
tcgggccccg ctgctgcgtt g   21

<210> 28
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> synthetic primer

<400> 28
ttgggccccg ctgctgcgtt g   21

<210> 29
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> synthetic primer

<400> 29
tgtgtcatgg gaggggtctc   20

<210> 30
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<223> synthetic primer

<400> 30
gctacaccgt gcgtacagct tcc   23

<210> 31
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<223> synthetic primer

<400> 31
gcagcctccc aggtttrtacg tcc   23

<210> 32
<211> 27
<212> DNA
<213> artificial Sequence

<220>
<223> synthetic primer

<400> 32
aacaacaaca aacaccaaag gctattg   27

<210> 33
<211> 23
<212> DNA
<213> Artificial sequence

<220>
<223> synthetic primer

<400> 33
cctaccggta ccagaacctg ttg   23

Claims

1. An attenuated dengue virus 3 (DEN3) comprising

   (a) a Δ30 mutation which deletes nucleotides 173-143 in the 3' untranslated region (3' UTR) that removes the terminal loop 2 (TL-2) homologous structure, and
   (b) a deletion mutation in the 3'-UTR,

   wherein the deletion mutation is selected from the group consisting of Δ31 which deletes nucleotides 258-228, Δ50 which deletes nucleotides 192-143, Δ61 which deletes nucleotides 173-113, Δ80 which deletes nucleotides 192-113, Δ86 which deletes nucleotides 228-143, Δ116A which deletes nucleotides 228-143, Δ146 which deletes nucleotides 258-113.

2. The attenuated dengue virus (DEN) of Claim 1, wherein the 3'UTR is derived from serotype DEN4 or DEN4Δ30.

3. An immunogenic composition comprising an attenuated dengue virus (DEN) according to any of Claims 1-2.

Patentansprüche

1. Abgeschwächtes Dengue-Virus 3 (DEN3), umfassend

    (a) eine Δ30 Mutation, die Nukleotiden 173-143 in der 3' nicht translatierten Region (3'-NTR) löscht, welche die homologe Struktur am terminalen Loop 2 (TL-2) entfernt, und
    (b) eine Deletionsmutation in der 3'-NTR,

    wobei die Deletionsmutation ausgewählt ist aus der Gruppe, bestehend aus Δ31, die Nukleotide 258-228 deletiert, Δ50, die Nukleotide 192-143 deletiert, Δ61, die Nukleotide 173-113 deletiert, Δ80, die Nukleotide 192-113 deletiert, Δ86, die Nukleotide 228-143 deletiert, Δ116A, die Nukleotide 228-143 deletiert, Δ146, die Nukleotide 258-113 deletiert.

2. Abgeschwächtes Dengue-Virus (DEN) nach Anspruch 1, wobei die 3'-NTR vom Serotyp DEN4 oder DEN4Δ30 abgeleitet ist.

3. Immunogene Zusammensetzung, umfassend ein abgeschwächtes Dengue-Virus (DEN) nach einem der Ansprüche 1-2.

Revendications

1. Virus de la dengue 3 (DEN3) atténué comprenant

    (a) une mutation Δ30 provoquant une délétion des nucléotides 173 à 143 dans la région non traduite en 3' (3' UTR) qui supprime la structure homologue de la boucle terminale 2 (TL 2), et
    (b) une mutation par délétion dans la région 3' UTR,

    dans lequel la mutation par délétion est choisie dans le groupe consistant en Δ31 provoquant une délétion des nucléotides 258 à 228, Δ50 provoquant une délétion des nucléotides 192 à 143, Δ61 provoquant une délétion des nucléotides 173 à 113, Δ80 provoquant une délétion des nucléotides 192 à 113, Δ86 provoquant une délétion des nucléotides 228 à 143, Δ116A provoquant une délétion des nucléotides 228 à 143, Δ146 provoquant une délétion des nucléotides 258 à 113.

2. Le virus de la dengue (DEN) atténué de la revendication 1, dans lequel la région 3'UTR est dérivée du sérotype DEN4 ou DEN4Δ30.

3. Composition immunogène comprenant un virus de la dengue (DEN) atténué selon l'une quelconque des revendications 1 à 2.

# A. Delete additional nucleotides from the 3' UTR:

a

Δ30

b

Δ86

c

Δ31/30

B. Replace the 3' UTR of DEN3 with the UTR from DEN4Δ30:

Figure 1

Δ30

Figure 1a

Δ86

Figure 1b

Δ31/30

Figure 1c

DEN1 wt (WP)
GenBank: AY145121
ΔG = -96.6
(mfold v3.2: 1 0 10, P 175 0 10)

Figure 2

DEN2 wt (Tonga/74)
GenBank: AY744147
ΔG = -88.3
(mfold v3.2: 1 0 10, P 79 0 14, P 178 0 10)

Figure 3

TL-3

TL-2

TL-1

DEN3 wt (Sleman/78)
GenBank: AY648961
ΔG = -89.9
(mfold v3.2: 1 0 10, P 173 0 10)

Figure 4

DEN4 wt (814669)
GenBank: AF326573
ΔG = -98.8
(mfold v3.2: 1 0 4, P 82 0 15, P 168 0 20)

Figure 5

Figure 6

SL-2Δ30

DEN2Δ30
ΔG = -76.0
(mfold v3.2: 1 0 10, P 79 0 14, P 148 0 10)

Figure 7

Figure 8

SL-2Δ30

DEN4Δ30
ΔG = -80.4
(mfold v3.2: 1 0 4, P 82 0 15, P 137 0 20)

Figure 9

SL-3Δ31

SL-2Δ30

DEN1Δ30/31
ΔG = -71.3
(mfold v3.2: 1 0 10, P 114 0 10)

Figure 10

SL-3Δ31

SL-2Δ30

DEN2Δ30/31
ΔG = -65.7
(mfold v3.2: 1 0 10, P 48 0 14, P 117 0 10)

Figure 11

Figure 12

Figure 13

5'- U-A-A-A-A-A-C-C-C-C-G-C-A-C-A-A-C-A-A-C-A-A-A-C-A-G-C-A-U-A-U-U-G-A-C-G-C-G-C-A-G-C-U -3'

SL-2Δ86

DEN1Δ86
ΔG = -59.5
(mfold v3.2: 1 0 5, P 91 0 10)

Figure 14

SL-2Δ86

DEN2Δ86
ΔG = -58.6
(mfold v3.2: 1 0 10, P 93 0 10)

Figure 15

Figure 16

SL-2Δ86

DEN4Δ86
ΔG = -61.8
(mfold v3.2: 1 0 4, P 82 0 20)

Figure 17

Figure 18

Figure 19

REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

Patent documents cited in the description

- US 60837723 B **[0061]**

Non-patent literature cited in the description

- **GUBLER, D. J. ; M. MELTZER.** *Adv Virus Res,* 1999, vol. 53, 35-70 **[0002]**
- **BRINTON, M. A. et al.** *Virology,* 1986, vol. 153, 113-121 **[0003]**
- **HAHN, C. S. et al.** *J Mol Biol,* 1987, vol. 198, 33-41 **[0003]**
- **PROUTSKI, V. et al.** *Nucleic Acids Res,* 1997, vol. 25, 1194-1202 **[0003]**
- **RAUSCHER, S.** *RNA,* 1997, vol. 3, 779-791 **[0003]**
- **SHURTLEFF, A. et al.** *Virology,* 2001, vol. 281, 75-87 **[0003]**
- **MEN, R. et al.** *J Virol,* 1996, vol. 70, 3930-3937 **[0003] [0008]**
- **DURBIN, A. P. et al.** *Am J Trop Med Hyg,* 2001, vol. 65, 405-413 **[0003] [0035]**
- **SINGLETON P ; SAINSBURY D.** Dictionary of Microbiology and Molecular Biology. J. Wiley & Sons, 2001 **[0006]**
- Fields Virology. Lippincott Williams & Wilkins, 2001 **[0006]**
- Remington's Pharmaceutical Sciences. Mack Publishing Co, 1990 **[0023]**
- **SAMBROOK ; FRITSCH ; MANIATIS.** Molecular Cloning: A Laboratory Manual. Cold Spring Harbor Laboratory, 1989 **[0028]**
- **TYAGI ; KRAMER.** *Nature Biotechnology,* 1996, vol. 14, 303-308 **[0031]**
- **GUBLER DJ.** *Clin Microbiol Rev,* 1998, vol. 11, 480-496 **[0032]**
- **GUBLER DJ ; MELTZER M.** *Adv Virus Res,* 1999, vol. 53, 35-70 **[0032]**
- Dengue Haemorrhagic Fever: Diagnosis, Treatment, Prevention and Control. WHO, 1997 **[0032]**
- Flaviviridae: The viruses and their replication. **RICE CM.** Fields Virology. Lippincott-Raven Publishers, 1996, 931-959 **[0032] [0033]**
- Yellow fever. **MONATH TP.** Vaccines. W.B. Saunders Co, 1999, 815-879 **[0034]**
- **BLANEY JE et al.** *Viral Immunol.,* 2006, vol. 19, 10-32 **[0035] [0047] [0053] [0055]**
- **DURBIN, AP et al.** *Am J Trop Med Hyg,* 2001, vol. 65, 405-413 **[0035]**
- **WHITEHEAD SS et al.** *J Virol,* 2003, vol. 77, 1653-1657 **[0035]**
- **BLANEY JE et al.** *Am J Trop Med Hyg,* 2004, vol. 71, 811-821 **[0035] [0036] [0038] [0047] [0057]**
- **BLANEY JE et al.** *BMC Inf Dis,* 2004, vol. 4, 39 **[0035]**
- **DURBIN et al.** *J Inf Dis,* 2005, vol. 191, 710-718 **[0035]**
- **WHITEHEAD SS et al.** *Vaccine,* 2003, vol. 21, 4307-4316 **[0035]**
- **BLANEY JE et al.** *Virology,* 2002, vol. 300, 125-139 **[0047]**
- **HANLEY et al.** *Vaccine,* 2004, vol. 22, 3440-3448 **[0047] [0049]**
- **HANLEY et al.** *Virology,* 2003, vol. 312, 222-232 **[0051]**
- **TROYER J.M.** *Am. J. Trop. Med. Hyg.,* 2001, vol. 65, 414-9 **[0058]**